CSIMarket
 
Cyclo Therapeutics Inc   (CYTH)
Other Ticker:  
 
 
Price: $1.6000 $-0.05 -3.030%
Day's High: $1.71 Week Perf: -1.23 %
Day's Low: $ 1.40 30 Day Perf: -4.19 %
Volume (M): 236 52 Wk High: $ 2.57
Volume (M$): $ 377 52 Wk Avg: $1.41
Open: $1.55 52 Wk Low: $0.67



 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 16
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Cyclo Therapeutics Inc
Cyclo Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for rare diseases. The company utilizes a proprietary drug delivery technology called Trappsol Cyclo to develop treatments for various diseases that currently have limited or no treatment options. Cyclo Therapeutics is primarily focused on developing therapies for diseases that affect the central nervous system, including diseases such as Niemann-Pick Disease Type C (NPC), Alzheimer's disease, and stroke. The company's goal is to improve the lives of patients with rare diseases by providing effective and safe therapies that can potentially slow down or halt the progression of these diseases.


   Company Address: 6714 NW 16th Street, Suite B Gainesville 32653 FL
   Company Phone Number: 418-8060   Stock Exchange / Ticker: NASDAQ CYTH
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cyclo Therapeutics Inc

CYTH Sees Impressive Revenue Surge and Deficit Reduction in Q4 2023

Cyclo Therapeutics Inc, a Biotechnology & Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, down from $-0.48 per share in the same reporting season the previous year.
Unlike many other entities in the Biotechnology & Pharmaceuticals sectors, which are experiencing declining top-line and receding transactions, Cyclo Therapeutics Inc has managed to shine in the fourth quarter. This is a positive development for the company, as it signifies its ability to navigate obstacles and maintain growth.

Cyclo Therapeutics Inc

Cyclo Therapeutics Inc. Unveils Remarkable Turnaround as Deficit Fades in Q3 2023

Cyclo Therapeutics Inc, a biotechnology and pharmaceutical company, recently released its financial report for the third quarter of 2023. Despite facing some challenges, the company managed to improve its earnings per share (EPS) and saw a significant increase in revenue compared to the previous year.
According to the report, CYTH's EPS rose to $-0.29 in the third quarter of 2023, representing an improvement from the $-0.33 per share in the preceding financial reporting period. This positive growth in EPS is certainly encouraging for the company and its investors, as it indicates an improvement in profitability.

Cyclo Therapeutics Inc

Cyclo Therapeutics Inc's Fiscal Q2 2023 Report: Decreased Losses but Revenue Drops, Raising Concerns over Net Deficit

Cyclo Therapeutics Inc, a biotechnology company focused on developing medications for rare diseases, recently released its fiscal second quarter earnings report for 2023. While the company experienced a decrease in its loss per share compared to the previous year, there were concerns regarding the drop in revenue and the higher net deficit.
In terms of earnings per share (EPS), Cyclo Therapeutics showed signs of improvement. The company reported a loss per share of $-0.33, which was lower than the loss per share of $-0.41 from the same period last year. Additionally, the EPS improved from $-0.46 per share in the preceding reporting period.

Cyclo Therapeutics Inc

Cyclo Therapeutics Inc Faces Fiscal Challenges in Q1 2023 as Accounts Receivable Collection Declines

Cyclo Therapeutics Inc, a company in the Basic Materials sector, has seen a decline in its ability to collect accounts receivable sequentially in the Mar 31 2023 quarter. The new figure of 5.38 is lower than the previous quarter, indicating a more challenging environment. However, it is still far from being a concerning development. The average receivable collection period for the Mar 31 2023 quarter is now 68 days, which is slightly higher than the previous quarter's 65 days.
In comparison to other companies within the Basic Materials sector, Cyclo Therapeutics Inc still has room for improvement, as other companies exhibit higher receivables turnover ratios. Nevertheless, the company's overall receivables turnover ratio ranking has improved to 181, compared to the fourth quarter of 2022.






 

Cyclo Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cyclo Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Cyclo Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com